<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26291059</article-id><article-id pub-id-type="pmc">4651137</article-id><article-id pub-id-type="pii">bjc2015289</article-id><article-id pub-id-type="doi">10.1038/bjc.2015.289</article-id><article-categories><subj-group subj-group-type="heading"><subject>Epidemiology</subject></subj-group></article-categories><title-group><article-title>Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish
section of the ERSPC</article-title><alt-title alt-title-type="running">Polygenic risk and overdiagnosis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pashayan</surname><given-names>Nora</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Pharoah</surname><given-names>Paul DP</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schleutker</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Talala</surname><given-names>Kirsi</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tammela</surname><given-names>Teuvo LJ</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000e4;&#x000e4;tt&#x000e4;nen</surname><given-names>Liisa</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Harrington</surname><given-names>Patricia</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tyrer</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Eeles</surname><given-names>Rosalind</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Duffy</surname><given-names>Stephen W</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="author-notes" rid="note1"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Auvinen</surname><given-names>Anssi</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="author-notes" rid="note1"><sup>9</sup></xref></contrib><aff id="aff1"><label>1</label><institution>Department of Applied Health Research, University
College London</institution>, 1-19 Torrington Place, London
WC1E 7HB, <country>UK</country></aff><aff id="aff2"><label>2</label><institution>Centre for Cancer Genetic Epidemiology, Department of
Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory</institution>,
Worts Causeway, Cambridge
CB1 8RN, <country>UK</country></aff><aff id="aff3"><label>3</label><institution>Department of Medical Biochemistry and Genetics,
University of Turku</institution>, Turku
FI20014, <country>Finland</country></aff><aff id="aff4"><label>4</label><institution>Finnish Cancer Registry</institution>, Helsinki
FI 00130, <country>Finland</country></aff><aff id="aff5"><label>5</label><institution>Department of Surgery, Tampere University Hospital
and School of Medicine, University of Tampere</institution>, Tampere
FI 33014, <country>Finland</country></aff><aff id="aff6"><label>6</label><institution>Division of Genetics and Epidemiology, The Institute
of Cancer Research &#x00026; Royal Marsden NHS Foundation Trust</institution>, London
SM2 5NG, <country>UK</country></aff><aff id="aff7"><label>7</label><institution>Centre for Cancer Prevention, Mathematics and
Statistics, Wolfson Institute of Preventive Medicine, Queen Mary University of London</institution>,
Charterhouse Square, London
EC1M 6BQ, <country>UK</country></aff><aff id="aff8"><label>8</label><institution>School of Health Sciences, University of
Tampere</institution>, Tampere
FI 33014, <country>Finland</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>n.pashayan@ucl.ac.uk</email></corresp><fn fn-type="present-address" id="note1"><label>9</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="ppub"><day>29</day><month>09</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>20</day><month>08</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>9</month><year>2015</year></pub-date><volume>113</volume><issue>7</issue><fpage>1086</fpage><lpage>1093</lpage><history><date date-type="received"><day>02</day><month>04</month><year>2015</year></date><date date-type="rev-recd"><day>02</day><month>07</month><year>2015</year></date><date date-type="accepted"><day>11</day><month>07</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Cancer Research UK</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><!--author-paid--><license-p>This work is licensed under the Creative Commons Attribution 4.0 International
License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license></permissions><abstract><sec><title>Background:</title><p>We derived estimates of overdiagnosis by polygenic risk groups and examined whether polygenic
risk-stratified screening for prostate cancer reduces overdiagnosis.</p></sec><sec><title>Methods:</title><p>We calculated the polygenic risk score based on genotypes of 66 known prostate cancer loci for
4967 men from the Finnish section of the European Randomised Study of Screening for Prostate Cancer.
We stratified the 72&#x02009;072 men in the trial into those with polygenic risk below and above the
median. Using a maximum likelihood method based on interval cancers, we estimated the mean sojourn
time (MST) and episode sensitivity. For each polygenic risk group, we estimated the proportion of
screen-detected cancers that are likely to be overdiagnosed from the difference between the observed
and expected number of screen-detected cancers.</p></sec><sec><title>Results:</title><p>Of the prostate cancers, 74&#x00025; occurred among men with polygenic risk above population
median. The sensitivity was 0.55 (95&#x00025; confidence interval (CI) 0.45&#x02013;0.65) and MST 6.3
(95&#x00025; CI 4.2&#x02013;8.3) years. The overall overdiagnosis was 42&#x00025; (95&#x00025; CI
37&#x02013;52) of the screen-detected cancers, with 58&#x00025; (95&#x00025; CI 54&#x02013;65) in men with
the lower and 37&#x00025; (95&#x00025; CI 31&#x02013;47) in those with higher polygenic risk.</p></sec><sec><title>Conclusion:</title><p>Targeting screening to men at higher polygenic risk could reduce the proportion of cancers
overdiagnosed.</p></sec></abstract><kwd-group><kwd>ERSPC-Finland</kwd><kwd>overdiagnosis</kwd><kwd>polygenic risk</kwd><kwd>prostate cancer</kwd><kwd>stratified screening</kwd></kwd-group></article-meta></front><body><p>At 13 years of follow-up, the European Randomised Study of Screening for Prostate Cancer (ERSPC)
showed a 21&#x00025; relative reduction in prostate cancer mortality in favour of screening, with one
prostate cancer death prevented and 27 additional cases detected per 781 men invited to screening
(<xref ref-type="bibr" rid="bib16">Schroder <italic>et al</italic>, 2014</xref>). The number needed to detect and the
number needed to invite to prevent one prostate cancer death were less at 13 years than at 9 and 11
years of follow-up. Despite the improvement in the absolute benefit of screening, concerns about the
negative consequences of screening, mainly overdiagnosis and treatment of overdiagnosed cancers,
remain obstacles for large-scale screening. An overdiagnosed cancer is defined as one that would not
have presented clinically in a person's lifetime in the absence of screening. Developing
methods to reduce overdiagnosis remains crucial for diminishing the adverse effects of
screening.</p><p>To date, genome-wide association studies have identified 100 prostate cancer susceptibility loci,
which explain &#x0223c;33&#x00025; of the familial risk of prostate cancer in population of European
ancestry (<xref ref-type="bibr" rid="bib1">Al Olama <italic>et al</italic>, 2014</xref>). Assuming a log-additive
model of interaction between loci, the currently known loci define a polygenic risk profile that
could be used for risk stratification (<xref ref-type="bibr" rid="bib14">Pharoah <italic>et al</italic>, 2008</xref>;
<xref ref-type="bibr" rid="bib11">Pashayan <italic>et al</italic>, 2011</xref>). Men at 90th and 99th percentile of
the risk distribution are at 2.9- and 5.7-fold increased risk for prostate cancer compared with the
average population (<xref ref-type="bibr" rid="bib1">Al Olama <italic>et al</italic>, 2014</xref>).</p><p>A personalised screening strategy based on age and genetic risk has the potential to improve the
efficiency of the screening programme (<xref ref-type="bibr" rid="bib11">Pashayan <italic>et al</italic>, 2011</xref>)
and reduce its adverse consequences (<xref ref-type="bibr" rid="bib12">Pashayan <italic>et al</italic>, 2015</xref>).
A mathematical modelling study using UK-based prevalent screen and incident cancer data has shown
that the proportion of screen-detected cancers likely to be overdiagnosed varies inversely by
polygenic risk (<xref ref-type="bibr" rid="bib12">Pashayan <italic>et al</italic>, 2015</xref>). However, the
estimates of overdiagnosis were based on mean sojourn time (MST) and test sensitivity derived from
the published literature. Using screening trial data from the Finnish section of ERSPC, this study
aims to estimate MST and sensitivity and then use these estimates to derive the probability of
overdiagnosis by polygenic risk. This is to examine whether a risk-stratified screening strategy
reduces the proportion of cancers overdiagnosed.</p><sec><title>Materials and Methods</title><sec><title>Study participants</title><p>The Finnish Prostate Cancer Screening Trial is the largest component of the ERSPC. The trial
population and the protocol have been described in detail elsewhere (<xref ref-type="bibr" rid="bib7">Finne
<italic>et al</italic>, 2003</xref>). Briefly, during 1996 and 1999, a total of 80&#x02009;458 men aged
55, 59, 63, and 67 years were identified from the Finnish Population Registry and of whom
80&#x02009;176 were randomised to either the screening arm (<italic>N</italic>=31&#x02009;875) or the
control arm (<italic>N</italic>=48&#x02009;301). Men in the screening arm were invited for serum
prostate specific antigen (PSA) testing every 4 years up to three times until age 71 years. The
study protocol was approved by the ethical committees of Helsinki University Hospital and Tampere
University Hospital. <xref ref-type="fig" rid="fig1">Figure 1</xref> presents the number of men in the trial
and cancers detected.</p><p>Men were referred for transrectal ultrasound-guided biopsy if the PSA value was
&#x02a7e;4.0&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup> or the PSA was
3.0&#x02013;3.99&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup> with suspicious findings on digital rectal
examination (in 1996&#x02013;1998) or with free/total PSA ratio &#x0003c;0.16 (since 1999). Initially,
sextant biopsies were used, and from 2002, 10 to 12 biopsy cores were taken.</p><p>Incident cancers diagnosed among the controls and the non-participants, and interval cancers were
identified through record linkage to the nationwide population-based Finnish Cancer Registry, which
has almost complete coverage of all solid cancers diagnosed in Finland (<xref ref-type="bibr" rid="bib18">Teppo
<italic>et al</italic>, 1994</xref>). An interval cancer was defined as cancer diagnosed in the interval
1-4 years after screening attendance. Cancers in non-participants and in those diagnosed more than 4
years after the previous screen were not regarded as interval cancers. Cancers that were not
diagnosed through organised screening were referred to as clinically diagnosed.</p><p>Prostate cancer was classified as localised disease with tumour-node-metastasis (TNM) stage T1-2
N0 M0; and advanced disease (regional-distant) with stage T3 and above or any T N1 M1; as
non-aggressive tumour, Gleason score &#x0003c;7, and aggressive tumour, Gleason score &#x02a7e;7.</p><p>The follow-up for this analysis was until 31 December 2011 and the median duration of follow-up
was 13 years.</p></sec><sec><title>Genotyping and quality control</title><p>At the time of genotyping, there were 70 prostate cancer susceptibility variants identified
through genome-wide association studies. The analysis was based on 66 of these variants (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 1S</xref>) for a sample of the trial participants, 1089 men with
prostate cancer and 3878 men without prostate cancer. Genotyping platform (<xref ref-type="bibr" rid="bib20">Wang
<italic>et al</italic>, 2009</xref>; <xref ref-type="bibr" rid="bib5">Eeles <italic>et al</italic>, 2013</xref>) and
quality control are described in the <xref ref-type="supplementary-material" rid="sup1">Supplementary File</xref>.</p></sec><sec><title>Polygenic risk score and absolute risk calculations</title><p>A polygenic risk score (PRS) for each individual was calculated as:</p><p>
<disp-formula id="equ1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2015289e1.jpg"/></disp-formula>
</p><p>where <italic>&#x003b2;</italic><sub><italic>i</italic></sub> is the per-allele log-odds ratio for locus <italic>i</italic>,
<italic>x</italic><sub><italic>ij</italic></sub> represents the number of risk alleles (i.e., 0, 1 or 2) carried by
each individual <italic>j</italic> at locus <italic>i</italic>, and <italic>n</italic> is the number of loci.</p><p>The risk conferred by each of the variants is assumed to be allele dose-dependent with a
multiplicative (log-additive) effect on a relative-risk scale (<xref ref-type="bibr" rid="bib13">Pharoah <italic>et
al</italic>, 2002</xref>). Under the multiplicative model the distribution of polygenic risk in the
population at birth follows the normal distribution when relative risk is plotted on a logarithmic
scale, with mean, <italic>&#x003bc;</italic>, and variance <italic>&#x003c3;</italic><sup>2</sup>. We set the mean,
<italic>&#x003bc;</italic> =&#x02212;<italic>&#x003c3;</italic><sup>2</sup>/2, so that the mean relative risk in
the population at birth is equal to unity. The distribution of relative risk among cases at young
ages is also log-normal with the same variance, but with larger mean, <italic>&#x003bc;</italic> &#x0002b;
<italic>&#x003c3;</italic><sup>2</sup> (<xref ref-type="bibr" rid="bib13">Pharoah <italic>et al</italic>, 2002</xref>).</p></sec><sec><title>Estimating overdiagnosis</title><sec><title>Mean sojourn time and sensitivity of PSA</title><p>Assuming exponential distribution of sojourn time, we estimated the sensitivity and the MST by
the maximum likelihood method of Walter and Day (<xref ref-type="bibr" rid="bib19">Walter and Day,
1983</xref>). The likelihood was evaluated over a two-dimensional grid of values of sensitivity,
<italic>S</italic>, and of inverse of MST, <italic>&#x003bb;</italic>. The observed incidence of interval cancers was
assumed to follow a Poisson process with an expected incidence of interval cancer that depends on
<italic>S</italic> and <italic>&#x003bb;</italic>, as such:</p><p>
<disp-formula id="equ2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2015289e2.jpg"/></disp-formula>
</p><p>where <italic>I</italic><sub>int</sub><italic>(t)</italic> is the expected incidence rate of interval cancers at
time <italic>t</italic>, and <italic>I&#x0002a;</italic> is the underlying incidence rate of prostate cancer in the
absence of screening, derived from the observed incidence rate in the control arm. Here,
person-years at risk were calculated from time of randomisation to time of prostate cancer
diagnosis, death or censoring date (31 December 2011), whichever occurred first.</p><p>To calculate the 95&#x00025; confidence level (CI), we identified the combinations of values of
<italic>S</italic> and <italic>&#x003bb;</italic> for which the log likelihood was 1.92 less than the maximum value
(<xref ref-type="bibr" rid="bib2">Day and Walter, 1984</xref>).</p><p>As the maximum likelihood approach is based on interval cancers, the derived estimates of
<italic>S</italic> and <italic>&#x003bb;</italic> refer to non-overdiagnosed cancers. Also, given how interval
cancers were defined in this study, the sensitivity refers to episode sensitivity, that is,
performance of the test and the diagnostic work up (<xref ref-type="bibr" rid="bib8">Hakama <italic>et al</italic>,
2007</xref>).</p></sec><sec><title>Expected number of non-overdiagnosed screen-detected cancers</title><p>Given <italic>S</italic> and <italic>&#x003bb;</italic>, we estimated the expected prevalence and incidence of
non-overdiagnosed cancers at first and subsequent screens, as such:</p><p>Expected prevalence:</p><p>
<disp-formula id="equ3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2015289e3.jpg"/></disp-formula>
</p><p>Expected incidence at second screen:</p><p>
<disp-formula id="equ4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2015289e4.jpg"/></disp-formula>
</p><p>Expected incidence at third screen:</p><p>
<disp-formula id="equ5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2015289e5.jpg"/></disp-formula>
</p><p>We applied the expected prevalence and incidence rate to the number of men screened at each
round, and estimated the expected number of non-overdiagnosed cancers. If <italic>O</italic> is the observed
number of screen-detected cancers, and <italic>E</italic> is the expected number of non-overdiagnosed
cancers, then the proportion of screen-detected cancers likely to be overdiagnosed would be <inline-formula id="equ6"><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2015289e6.jpg"/></inline-formula>.</p></sec><sec><title>Estimation of overdiagnosis by PRS</title><p>The PRS was available on subsample of men with screen-detected cancers, interval cancers, and
incident cancers, and on subsample of men without cancer. We stratified men with and without
prostate cancer into two risk groups: below and above 50th percentile of polygenic risk distribution
among the population, hereafter referred to as lower and higher risk groups, respectively. In the
subsamples, the proportions in the higher risk groups are shown in <xref rid="tbl1" ref-type="table">Table
1</xref>. We used these proportions as sampling fractions to derive the likely proportion of the
study population with and without prostate cancer in the lower and higher risk groups. To estimate
the baseline incidence rate of prostate cancer by polygenic risk groups, we derived the relative
rate of clinical cancers in the two risk groups using information on interval cancer as such:</p><p>
<disp-formula id="equ7"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2015289e7.jpg"/></disp-formula>
</p><p>where <italic>n</italic><sub>h</sub> and <italic>n</italic><sub>l</sub> are the number of interval cancers in the
higher and lower risk groups, respectively; and <italic>N</italic><sub>h</sub> and <italic>N</italic><sub>l</sub>
are the number of men screened in the higher and lower risk groups, respectively.</p><p>Then the overall rate would be:</p><p>
<disp-formula id="equ8"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2015289e8.jpg"/></disp-formula>
</p><p>where <italic>&#x003b1;</italic><sub><italic>p</italic></sub>is the sampling fraction for men free of cancer in the
screening arm and in the higher risk group.</p><p>We derived separate estimates of overdiagnosis for those in the lower and higher risk groups by
repeating the steps used to estimate the overall overdiagnosis.</p></sec><sec><title>Sensitivity analysis</title><p>In the Finnish Prostate Cancer Screening Trial, 19&#x00025; of men in the control group had PSA
test in the first 4 years. In a sensitivity analysis, we estimated the baseline incidence rate after
excluding men with cancer detected following PSA testing, and re-estimated overdiagnosis by
polygenic risk groups.</p></sec></sec></sec><sec><title>Results</title><p>The distribution of PRS based on 66 prostate cancer susceptibility loci had mean (scaled mean) of
&#x02212;0.16 (&#x02212;0.20) and variance of 0.40 among men with no prostate cancer and mean of 0.30
(0.20) and variance of 0.40 among men with the cancer. There was no statistically significant
difference in the mean PRS of men with screen-detected <italic>vs</italic> clinically diagnosed cancer
(<italic>t</italic>-test <italic>P</italic>=0.137) (<xref rid="tbl2" ref-type="table">Table 2</xref>). The polygenic risk
scores at the 25th, 50th, and 75th percentiles of the risk distribution among men with no prostate
cancer accounted for 17&#x00025;, 26&#x00025;, and 48&#x00025; of the cases, respectively. Thus, men in
the high-risk group (above the 50th centile) accounted for 74&#x00025; of the cases.</p><p>The PRS was available on 35&#x00025; of men with screen-detected cancer and 9&#x00025; of men with
cancer in the control arm. The proportions of men with screen-detected cancer with advanced stage,
Gleason score &#x02a7e;7, or PSA &#x02a7e;4 were comparable between the trial participants overall and the
subsample of men with PRS. However, out of clinically diagnosed cancers, the subsample with PRS had
lower proportion of cancers with advanced stage or Gleason score &#x02a7e;7 compared with all clinically
diagnosed cancers (<xref rid="tbl3" ref-type="table">Table 3</xref>).</p><p>PSA level varied by polygenic risk, 18&#x00025; of men in the higher polygenic risk group compared
with 7&#x00025; of men in the lower risk group had PSA &#x02265;4&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup>
(<italic>P</italic>&#x0003c;0.001). However, after adjusting for stage and Gleason score, there was no
statistically significant association between polygenic risk group and PSA categories (odds
ratio=1.35, 95&#x00025; CI 0.89-2.04). Among the screen-detected cancers, there was
statistically significant association between polygenic risk group and stage
(<italic>P</italic>=0.046) and Gleason score categories (<italic>P</italic>=0.005). However, similar
association was not seen among the clinically diagnosed cancers (<xref rid="tbl3" ref-type="table">Table
3</xref>).</p><p>Overall, higher polygenic risk was associated with significantly increased odds of Gleason score
&#x02a7e;7 tumours (odds ratio=1.56, 95&#x00025; CI 1.15&#x02013;2.10) but not with advanced stage
(odds ratio=1.36, 95&#x00025; CI 0.85-2.16).</p><p>The baseline incidence rate of prostate cancer in the control group was 6.17 cases per 1000
person-years (4150 cases/672&#x02009;610 person-years from time of randomisation to censoring
date). The estimated baseline incidence rates of prostate cancer were 2.47 and 9.90 cases per 1000
person-years in the lower and higher risk groups, respectively. The likelihood for the expected
incidence rate of interval cancers was maximised for sensitivity of 0.55 (95&#x00025; CI 0.45-0.65)
and <italic>&#x003bb;</italic> of 0.16 (95&#x00025; CI 0.12-0.24) (<xref rid="tbl4" ref-type="table">Table 4</xref>).</p><p>Given these parameters, the expected number of screen-detected non-overdiagnosed cancers after
three rounds of screening would be 950. As such 42&#x00025; (95&#x00025; CI 37-52; 696 out of 1646) of
the observed screen-detected cancers would likely be overdiagnosed (<xref rid="tbl5" ref-type="table">Table
5</xref>).</p><p>The lower risk group would account for 50&#x00025; of the screening episodes
(<italic>N</italic>=26&#x02009;186) in the trial and almost 26&#x00025; of the observed screen-detected
cancers (<italic>N</italic>=453). A baseline incidence of 0.00247, <italic>S</italic> of 0.55 and
<italic>&#x003bb;</italic> of 0.16, the expected number of non-overdiagnosed cancers would be 191. Hence,
58&#x00025; (95&#x00025; CI 54-65; 262 out of 453) of the screen-detected cancers in the lower PRS
group would likely be overdiagnosed.</p><p>The higher risk group would account for almost 50&#x00025; of the screening episodes
(<italic>N</italic>=25&#x02009;957) in the trial and almost 74&#x00025; of the observed screen-detected
cancers (<italic>N</italic>=1193). Using baseline incidence rate of 0.00990, <italic>S</italic> of 0.55 and
<italic>&#x003bb;</italic> of 0.16, the expected number of non-overdiagnosed cancers would be 756.
Correspondingly, 37&#x00025; (95&#x00025; CI 31-47; 437 out of 1193) of the screen-detected cancers
would likely be overdiagnosed.</p><p>At 13 years of follow-up, the overall overdiagnosed cases per 1000 men screened were 29, with 22
and 37 in the lower and higher polygenic risk groups, respectively.</p><p>Targeting screening to men in the higher risk group would miss 191 non-overdiagnosed cancers,
while avoiding 262 overdiagnosed cancers. Targeted screening would reduce the overall cases
overdiagnosed in the population from 29 (696 out of 23&#x02009;771) to 18 (437 out of 23&#x02009;771)
per 1000 men.</p><p>In a sensitivity analysis, after excluding 9129 from the control group who had PSA test in the
first 4 years and the expected subsequent 946 cancer diagnoses, the baseline incidence rate of
prostate cancer in the control group was 5.87 cases per 1000 person-years (3204
cases/545&#x02009;148 person-years from time of randomisation to censoring date). With baseline
incidence rate of 0.00587, the <italic>S</italic> and <italic>&#x003bb;</italic> were derived as 0.52 and 0.16,
respectively. With these parameters, overall overdiagnosis was estimated as 47&#x00025;, with
62&#x00025; in the lower risk group and 37&#x00025; in the higher risk group.</p></sec><sec><title>Discussion</title><p>This study, based on the Finnish prostate cancer screening trial data, suggests that the
proportion of screen-detected cancers that are likely to be overdiagnosed is inversely related to
polygenic risk, that is, proportion overdiagnosed decreases with increase in polygenic risk. The
proportion of screen-detected cancers that are likely to be overdiagnosed is estimated to be
37&#x00025; lower in men with polygenic risk higher than the average population risk than in men with
lower polygenic risk. In the Finnish population-based screening trial with three rounds of
screening, 31&#x02009;700 screening episodes would detect 1000 cancers in these men, of which 577
would likely be non-overdiagnosed and 423 overdiagnosed. A polygenic risk-stratified screening
programme would involve polygenic profiling of all men for risk stratification. Then the screening
test, the PSA, would be offered to the strata of men above a certain polygenic risk threshold. As
such a subset of men are offered PSA screening. Targeting screening to men in the higher polygenic
risk group is estimated to reduce screening episodes by half while detecting 80&#x00025; of the
non-overdiagnosed cancers and reducing overdiagnosed cancers by 38&#x00025; at a cost of missing
20&#x00025; of the non-overdiagnosed cancers. That is, for every non-overdiagnosed cancer not
detected through screening, almost two (37/20) overdiagnosed cases could be avoided.</p><p>We have reported similar inverse association between quartiles of polygenic risk and
overdiagnosis using different analysis approach and using data from the UK on prevalence screening
and incident cancers only (<xref ref-type="bibr" rid="bib12">Pashayan <italic>et al</italic>, 2015</xref>). However,
the study was limited by taking MST and test sensitivity values from different sources. In this
study, having randomised screening trial data with information on interval cancers, we estimated
simultaneously the MST and episode sensitivity for non-overdiagnosed cancers and from them derived
the probability of overdiagnosis in the Finnish trial setting. This enhances the validity of our
results. We do acknowledge, however, that the present results rely on a number of assumptions, and
that they remain subject to considerable uncertainty. There is a need for continued development of
rigorous methods of estimation of overdiagnosis, including reliable confidence interval estimation
and for further data on screened and unscreened populations with polygenic risk measured.</p><p>Although the proportion of screen-detected cancers that are likely to be overdiagnosed decreased
with polygenic risk, the absolute rate of overdiagnosis increased with polygenic risk. This is
because majority of the cancers (74&#x00025;) occurred in the higher risk group. Although screening
was estimated to result in 67&#x00025; more overdiagnosed cancers in the higher compared with the
lower risk group (437 <italic>vs</italic> 262), it also resulted in almost 300&#x00025; more
non-overdiagnosed cancers in the higher risk group (756 <italic>vs</italic> 191). Thus, overdiagnosis in the
higher risk group is estimated to be substantially smaller as a proportion of screen-detected
cancers, and would be expected to be correspondingly smaller in proportion to prostate cancer deaths
avoided.</p><p>We have used the maximum likelihood method to estimate MST of 6.2 years and episode sensitivity
of 55&#x00025;. All estimates of MST and sensitivity are subject to both sampling variation and
uncertainty due to other sources such as the distributional assumptions involved. Our estimates are
within the 95&#x00025; CI of previously reported estimates. <xref ref-type="bibr" rid="bib21">Wu <italic>et al</italic>
(2012)</xref> using multistate modelling with the same Finnish screening trial data have reported
MST of 7.7 (95&#x00025; CI 6.0-10.7) years and episode sensitivity of 43&#x00025; (95&#x00025; CI
35-51) for the first screening round and 60&#x00025; (95&#x00025; CI 48-72) for the second round. Our
estimate of overdiagnosis of 42&#x00025; is in line with the estimates from the ERSPC (<xref ref-type="bibr" rid="bib3">Draisma <italic>et al</italic>, 2003</xref>). Our analysis indicates that 2.9&#x00025; of men
screened with three rounds of screen are likely to be overdiagnosed. This estimate is comparable to
that of <xref ref-type="bibr" rid="bib21">Wu <italic>et al</italic> (2012)</xref> of 3.4&#x00025; (95&#x00025; CI
2.1-5.7). These figures are also consistent with other studies (<xref ref-type="bibr" rid="bib6">Etzioni <italic>et
al</italic>, 2002</xref>; <xref ref-type="bibr" rid="bib17">Telesca <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib4">Draisma <italic>et al</italic>, 2009</xref>; <xref ref-type="bibr" rid="bib10">Loeb <italic>et al</italic>,
2014</xref>).</p><p>It is of interest to know whether the natural history of the cancer varies by genetic risk.
However, the relatively small number of cases, particularly in the lower polygenic risk group,
limited precision of the sensitivity and MST estimates by polygenic risk group. As the majority of
the cancers were in the higher polygenic risk group, then the estimated MST and sensitivity are
likely to reflect primarily those of that population. Preliminary analysis suggests similar episode
sensitivity and longer MST in the lower polygenic risk group. MST varying by polygenic risk is
plausible given the observed association between Gleason score and PRS. With longer sojourn time, we
would expect higher overdiagnosis (<xref ref-type="bibr" rid="bib4">Draisma <italic>et al</italic>, 2009</xref>) in
the lower risk group. Risk groups with longer MST may be offered less-frequent screening. As such
studying variation of MST with PRS is important for designing risk-tailored screening.</p><p>The subsample of men with genotyping data and clinically diagnosed cancer had less-aggressive and
less-advanced cancers than the remaining participants diagnosed clinically. Less-aggressive cancers
were associated with lower PRS. If our subsample had more aggressive cancers, then the proportion of
interval cancers and baseline incidence rate in the higher risk group would have been larger,
resulting in even lower estimate of overdiagnosis in the higher risk group.</p><p>Also, a sensitivity analysis accounting for some of the effect of contamination yielded almost
similar results.</p><p>In this study, we have used only polygenic risk profile for stratification. Further research is
needed to study the benefits, the harms, and cost-effectiveness of stratifying the population into
several risk strata based on polygenic risk combined with other risk factors, such as age, family
history, and baseline PSA (<xref ref-type="bibr" rid="bib9">Loeb, 2012</xref>; <xref ref-type="bibr" rid="bib15">Roobol and
Carlsson, 2013</xref>), and offering screening differentially (different starting age,
inter-screening interval, and screening modality) to each population stratum.</p><p>In summary, polygenic risk-stratified screening for prostate cancer could reduce the proportion
of cancers overdiagnosed. Targeting screening to men at higher polygenic risk could improve the
benefit to harm balance of screening.</p></sec></body><back><ack><p>NP is Cancer Research UK Clinician Scientist Fellow. The cost of genotyping was funded by Cancer
Research UK Clinician Scientist Fellowship (Grant &#x00023;C25773/A13065), and the COGS project. The
COGS project was funded through a European Commission's Seventh Framework Programme grant
(agreement number 223175 - HEALTH-F2-2009-223175), Cancer Research UK (C490/A10124), the UK
National Institute for Health Research Biomedical Research Centre at the University of Cambridge.
ERSPC-Finland has been financially supported by the Academy of Finland (Grant No 260931), Cancer
Society of Finland and Competitive Research Funding of the Pirkanmaa Hospital District. RE
acknowledges support from the NIHR to the Biomedical Research Centre at the Institute of Cancer
Research and the Royal Marsden NHS Foundation Trust. We thank the research team and participants of
the Finnish Prostate Cancer Screening Trial.</p><p>
<bold>Author contributions</bold>
</p><p>NP, PDP, and SD contributed to the conception of the study. SD designed the study, NP and SD
contributed to the analysis, and NP, PDP, SD, and AA contributed to the interpretation of the
findings, and NP drafted the manuscript. AA and TT are the principal investigators of the Finnish
Prostate Cancer Screening Trial. JS, PH, JT, and RE contributed in generating and providing the
genotyping data. KT and LM contributed in providing the trial data. PDP, JS, KT, TT, LM, PH, JT, RE,
SWD, and AA contributed in revising the manuscript. All authors have seen and approved the submitted
manuscript. NP had full access to all of the data in the study and takes responsibility for the
integrity and accuracy of the data analysis.</p></ack><fn-group><fn><p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies this paper on British
Journal of Cancer website (http://www.nature.com/bjc)</p></fn><fn fn-type="conflict"><p>TT has received grants and fees from Astellas, Janssen, Orion Pharma, and AMGEN. RE declares
receiving educational grant from GenProbe/Vista Diagnostics/Illumina; Honorarium &#x00026;
expenses to UK Cancer Convention October 2012 from Succint Communications; Medical Education support
to GU-ASCO meeting February 2013 from Janssen. All the remaining authors declare no conflict of
interest.</p></fn></fn-group><ref-list><ref id="bib1"><mixed-citation publication-type="journal">Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le ML, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Roder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokolorczyk D, Kluzniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G, Cook MB, Nakagawa H, Wiklund F, Kraft P, Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA (<year>2014</year>) <article-title>A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate
cancer</article-title>. <source>Nat Genet</source>
<volume>46</volume>(10): <fpage>1103</fpage>&#x02013;1109.<pub-id pub-id-type="pmid">25217961</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal">Day NE, Walter SD (<year>1984</year>) <article-title>Simplified models of screening for chronic disease: estimation procedures from mass
screening programmes</article-title>. <source>Biometrics</source>
<volume>40</volume>(1): <fpage>1</fpage>&#x02013;14.<pub-id pub-id-type="pmid">6733223</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal">Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, de Koning HJ (<year>2003</year>) <article-title>Lead times and overdetection due to prostate-specific antigen screening: estimates from the
European Randomized Study of Screening for Prostate Cancer</article-title>. <source>J Natl Cancer Inst</source>
<volume>95</volume>(12): <fpage>868</fpage>&#x02013;878.<pub-id pub-id-type="pmid">12813170</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal">Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H (<year>2009</year>) <article-title>Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods
and context</article-title>. <source>J Natl Cancer Inst</source>
<volume>101</volume>(6): <fpage>374</fpage>&#x02013;383.<pub-id pub-id-type="pmid">19276453</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal">Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le ML, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Roder MA, Nielsen SF, Bojesen SE, Siddiq A, FitzGerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC, Kote-Jarai Z, Easton DF (<year>2013</year>) <article-title>Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom
genotyping array</article-title>. <source>Nat Genet</source>
<volume>45</volume>(4): <fpage>385</fpage>&#x02013;391.<pub-id pub-id-type="pmid">23535732</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal">Etzioni R, Penson DF, Legler JM, di TD, Boer R, Gann PH, Feuer EJ (<year>2002</year>) <article-title>Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer
incidence trends</article-title>. <source>J Natl Cancer Inst</source>
<volume>94</volume>(13): <fpage>981</fpage>&#x02013;990.<pub-id pub-id-type="pmid">12096083</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal">Finne P, Stenman UH, Maattanen L, Makinen T, Tammela TL, Martikainen P, Ruutu M, Ala-Opas M, Aro J, Karhunen PJ, Lahtela J, Rissanen P, Juusela H, Hakama M, Auvinen A (<year>2003</year>) <article-title>The Finnish trial of prostate cancer screening: where are we now</article-title>? <source>BJU Int</source>
<volume>92</volume>(Suppl 2): <fpage>22</fpage>&#x02013;26.<pub-id pub-id-type="pmid">14983949</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal">Hakama M, Auvinen A, Day NE, Miller AB (<year>2007</year>) <article-title>Sensitivity in cancer screening</article-title>. <source>J Med Screen</source>
<volume>14</volume>(4): <fpage>174</fpage>&#x02013;177.<pub-id pub-id-type="pmid">18078561</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal">Loeb S (<year>2012</year>) <article-title>Use of baseline prostate-specific antigen measurements to personalize prostate cancer
screening</article-title>. <source>Eur Urol</source>
<volume>61</volume>(5): <fpage>875</fpage>&#x02013;876.<pub-id pub-id-type="pmid">22154726</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal">Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R (<year>2014</year>) <article-title>Overdiagnosis and overtreatment of prostate cancer</article-title>. <source>Eur Urol</source>
<volume>65</volume>(6): <fpage>1046</fpage>&#x02013;1055.<pub-id pub-id-type="pmid">24439788</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal">Pashayan N, Duffy SW, Chowdhury S, Dent T, Burton H, Neal DE, Easton DF, Eeles R, Pharoah P (<year>2011</year>) <article-title>Polygenic susceptibility to prostate and breast cancer: implications for personalised
screening</article-title>. <source>Br J Cancer</source>
<volume>104</volume>(10): <fpage>1656</fpage>&#x02013;1663.<pub-id pub-id-type="pmid">21468051</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="other">Pashayan N, Duffy SW, Neal DE, Hamdy FC, Donovan JL, Martin RM, Harrington P, Benlloch S, Amin Al OA, Shah M, Kote-Jarai Z, Easton DF, Eeles R, Pharoah PD (<year>2015</year>) <article-title>Implications of polygenic risk-stratified screening for prostate cancer on
overdiagnosis</article-title>. <source>Genet Medgim</source> e-pub ahead of print 8 January 2015 doi:10.1038/gim.2014.192.</mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal">Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA (<year>2002</year>) <article-title>Polygenic susceptibility to breast cancer and implications for prevention</article-title>. <source>Nat Genet</source>
<volume>31</volume>(1): <fpage>33</fpage>&#x02013;36.<pub-id pub-id-type="pmid">11984562</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal">Pharoah PD, Antoniou AC, Easton DF, Ponder BA (<year>2008</year>) <article-title>Polygenes, risk prediction, and targeted prevention of breast cancer</article-title>. <source>N Engl J Med</source>
<volume>358</volume>(26): <fpage>2796</fpage>&#x02013;2803.<pub-id pub-id-type="pmid">18579814</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal">Roobol MJ, Carlsson SV (<year>2013</year>) <article-title>Risk stratification in prostate cancer screening</article-title>. <source>Nat Rev Urol</source>
<volume>10</volume>(1): <fpage>38</fpage>&#x02013;48.<pub-id pub-id-type="pmid">23247693</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal">Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, De Koning HJ, Moss SM, Auvinen A (<year>2014</year>) <article-title>Screening and prostate cancer mortality: results of the European Randomised Study of
Screening for Prostate Cancer (ERSPC) at 13 years of follow-up</article-title>. <source>Lancet</source>
<volume>384</volume>(9959): <fpage>2027</fpage>&#x02013;2035.<pub-id pub-id-type="pmid">25108889</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal">Telesca D, Etzioni R, Gulati R (<year>2008</year>) <article-title>Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer
incidence trends</article-title>. <source>Biometrics</source>
<volume>64</volume>(1): <fpage>10</fpage>&#x02013;19.<pub-id pub-id-type="pmid">17501937</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal">Teppo L, Pukkala E, Lehtonen M (<year>1994</year>) <article-title>Data quality and quality control of a population-based cancer registry. Experience in
Finland</article-title>. <source>Acta Oncol</source>
<volume>33</volume>(4): <fpage>365</fpage>&#x02013;369.<pub-id pub-id-type="pmid">8018367</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal">Walter SD, Day NE (<year>1983</year>) <article-title>Estimation of the duration of a pre-clinical disease state using screening data</article-title>. <source>Am J Epidemiol</source>
<volume>118</volume>(6): <fpage>865</fpage>&#x02013;886.<pub-id pub-id-type="pmid">6650488</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal">Wang J, Lin M, Crenshaw A, Hutchinson A, Hicks B, Yeager M, Berndt S, Huang WY, Hayes RB, Chanock SJ, Jones RC, Ramakrishnan R (<year>2009</year>) <article-title>High-throughput single nucleotide polymorphism genotyping using nanofluidic Dynamic
Arrays</article-title>. <source>BMC Genomics</source>
<volume>10</volume>: <fpage>561</fpage>.<pub-id pub-id-type="pmid">19943955</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal">Wu GH, Auvinen A, Maattanen L, Tammela TL, Stenman UH, Hakama M, Yen AM, Chen HH (<year>2012</year>) <article-title>Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in
prostate cancer screening</article-title>. <source>Int J Cancer</source>
<volume>131</volume>(6): <fpage>1367</fpage>&#x02013;1375.<pub-id pub-id-type="pmid">22052356</pub-id></mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Information</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2015289x1.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p><bold>Flow chart of the Finnish Prostate Cancer Screening Trial.</bold> &#x0002a;Cancer diagnosed more than
4 years since the last screen; 282 men were excluded from randomisation because of death, or
prostate cancer diagnosis. Pca, prostate cancer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2015289f1"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Proportion of the study population with PRS and of those in the higher risk group</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">
<bold>No. (&#x00025;) with PRS</bold>
</th><th align="center" valign="top" charoff="50">
<bold>No. (&#x00025;) with PRS in the higher risk group</bold>
</th></tr></thead><tbody valign="top"><tr><td colspan="3" align="left" valign="top" charoff="50">
<bold>Screening arm</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Men with no prostate cancer <italic>N</italic>=21&#x02009;030</td><td align="center" valign="top" charoff="50">3877 (18.4)</td><td align="center" valign="top" charoff="50">1930 (49.8)</td></tr><tr><td align="left" valign="top" charoff="50">Screen-detected cancer at first round of screening <italic>N</italic>=686</td><td align="center" valign="top" charoff="50">173 (25.2)</td><td align="center" valign="top" charoff="50">131 (75.7)</td></tr><tr><td align="left" valign="top" charoff="50">Screen-detected cancer at subsequent rounds of screening <italic>N</italic>=960</td><td align="center" valign="top" charoff="50">406 (42.3)</td><td align="center" valign="top" charoff="50">285 (70.2)</td></tr><tr><td align="left" valign="top" charoff="50">Interval cancer <italic>N</italic>=525</td><td align="center" valign="top" charoff="50">115 (21.9)</td><td align="center" valign="top" charoff="50">92 (80.0)</td></tr><tr><td align="left" valign="top" charoff="50">Clinically diagnosed cancer &#x0003e;4 years after last screen <italic>N</italic>=565</td><td align="center" valign="top" charoff="50">34 (6.0)</td><td align="center" valign="top" charoff="50">25 (73.5)</td></tr><tr><td align="left" valign="top" charoff="50">Non-participants with clinically diagnosed cancer <italic>N</italic>=562</td><td align="center" valign="top" charoff="50">22 (3.9)</td><td align="center" valign="top" charoff="50">17 (77.3)</td></tr><tr><td align="left" valign="top" charoff="50">Non-participants with no cancer diagnosis <italic>N</italic>=7542</td><td align="center" valign="top" charoff="50">0 (0.0)</td><td align="center" valign="top" charoff="50">0 (0.0)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">
<bold>Control arm</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Clinically diagnosed cancer <italic>N</italic>=4150</td><td align="center" valign="top" charoff="50">339 (8.2)</td><td align="center" valign="top" charoff="50">250 (73.8)</td></tr><tr><td align="left" valign="top" charoff="50">No cancer <italic>N</italic>=44&#x02009;151</td><td align="center" valign="top" charoff="50">1 (0.0)</td><td align="center" valign="top" charoff="50">1 (100.0)</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviation: PRS=polygenic risk score.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Polygenic risk distribution among men with and without cancer in the Finnish screening
trial</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">
<bold>Mean</bold>
</th><th align="center" valign="top" charoff="50">
<bold>Scaled mean</bold>
<xref ref-type="fn" rid="t2-fn2">a</xref>
</th><th align="center" valign="top" charoff="50">
<bold>Variance</bold>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Men without prostate cancer <italic>N</italic>=3878</td><td align="center" valign="top" charoff="50">&#x02212;0.160</td><td align="center" valign="top" charoff="50">&#x02212;0.198</td><td align="center" valign="top" charoff="50">0.397</td></tr><tr><td align="left" valign="top" charoff="50">Men with prostate cancer <italic>N</italic>=1089</td><td align="center" valign="top" charoff="50">0.299</td><td align="center" valign="top" charoff="50">0.198</td><td align="center" valign="top" charoff="50">0.401</td></tr><tr><td align="left" valign="top" charoff="50">&#x02009;Men with screen-detected cancer <italic>N</italic>=579</td><td align="center" valign="top" charoff="50">0.272</td><td align="center" valign="top" charoff="50">0.172</td><td align="center" valign="top" charoff="50">0.394</td></tr><tr><td align="left" valign="top" charoff="50">&#x02009;Men with clinically detected cancer <italic>N</italic>=510</td><td align="center" valign="top" charoff="50">0.329</td><td align="center" valign="top" charoff="50">0.229</td><td align="center" valign="top" charoff="50">0.408</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Polygenic risk score is based on the known 66 prostate cancer susceptibility loci.</p></fn><fn id="t2-fn2"><label>a</label><p>By setting the mean polygenic relative risk in the population equal to unity.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Comparison of Gleason score, stage, and PSA categories among men in the trial and men with
PRS</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">
<bold>No. of men</bold>
<italic>
<bold>N</bold>
</italic>
<bold>(&#x00025;)</bold>
</th><th align="center" valign="top" charoff="50">
<bold>No. of men with PRS</bold>
<italic>
<bold>N</bold>
</italic>
<bold>(&#x00025;)</bold>
</th><th align="center" valign="top" charoff="50">
<italic>
<bold>P</bold>
</italic>
<bold>-value (</bold>
<italic>
<bold>Z</bold>
</italic>
<bold>-test)</bold>
</th><th align="center" valign="top" charoff="50">
<bold>Lower risk group</bold>
<italic>
<bold>N</bold>
</italic>
<bold>(&#x00025;)</bold>
</th><th align="center" valign="top" charoff="50">
<bold>Higher risk group</bold>
<italic>
<bold>N</bold>
</italic>
<bold>(&#x00025;)</bold>
</th><th align="center" valign="top" charoff="50">
<italic>
<bold>P</bold>
</italic>
<bold>value (</bold>
<italic>
<bold>&#x003c7;</bold>
</italic>
<sup>
<italic>
<bold>2</bold>
</italic>
</sup>
<bold>-square test)</bold>
</th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" valign="top" charoff="50">
<bold>Gleason score</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Overall</td><td align="center" valign="top" charoff="50"><italic>N</italic>=7268</td><td align="center" valign="top" charoff="50"><italic>N</italic>=1083</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td><td align="center" valign="top" charoff="50"><italic>N</italic>=288</td><td align="center" valign="top" charoff="50"><italic>N</italic>=795</td><td align="char" valign="top" char="." charoff="50">0.004</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Gleason score &#x0003c;7</td><td align="center" valign="top" charoff="50">3947 (54)</td><td align="center" valign="top" charoff="50">731 (68)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">214 (74)</td><td align="center" valign="top" charoff="50">517 (65)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Gleason score &#x02a7e;7</td><td align="center" valign="top" charoff="50">3321 (46)</td><td align="center" valign="top" charoff="50">352 (32)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">74 (26)</td><td align="center" valign="top" charoff="50">278 (35)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Screen-detected</td><td align="center" valign="top" charoff="50"><italic>N</italic>=1643</td><td align="center" valign="top" charoff="50"><italic>N</italic>=578</td><td align="char" valign="top" char="." charoff="50">0.645</td><td align="center" valign="top" charoff="50"><italic>N</italic>=163</td><td align="center" valign="top" charoff="50"><italic>N</italic>=415</td><td align="char" valign="top" char="." charoff="50">0.005</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Gleason score &#x0003c;7</td><td align="center" valign="top" charoff="50">1204 (73)</td><td align="center" valign="top" charoff="50">416 (72)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">131 (80)</td><td align="center" valign="top" charoff="50">285 (69)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Gleason score &#x02a7e;7</td><td align="center" valign="top" charoff="50">439 (27)</td><td align="center" valign="top" charoff="50">162 (28)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">32 (20)</td><td align="center" valign="top" charoff="50">130 (31)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Clinically diagnosed</td><td align="center" valign="top" charoff="50"><italic>N</italic>=5625</td><td align="center" valign="top" charoff="50"><italic>N</italic>=505</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td><td align="center" valign="top" charoff="50"><italic>N</italic>=125</td><td align="center" valign="top" charoff="50"><italic>N</italic>=380</td><td align="char" valign="top" char="." charoff="50">0.284</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Gleason score &#x0003c;7</td><td align="center" valign="top" charoff="50">2743 (49)</td><td align="center" valign="top" charoff="50">315 (62)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">83 (66)</td><td align="center" valign="top" charoff="50">232 (61)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Gleason score &#x02a7e;7</td><td align="center" valign="top" charoff="50">2882 (51)</td><td align="center" valign="top" charoff="50">190 (38)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">42 (34)</td><td align="center" valign="top" charoff="50">148 (39)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50">
<bold>Stage</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Overall</td><td align="center" valign="top" charoff="50"><italic>N</italic>=7448</td><td align="center" valign="top" charoff="50"><italic>N</italic>=1089</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td><td align="center" valign="top" charoff="50"><italic>N</italic>=289</td><td align="center" valign="top" charoff="50"><italic>N</italic>=800</td><td align="char" valign="top" char="." charoff="50">0.198</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Localised stage</td><td align="center" valign="top" charoff="50">5970 (80)</td><td align="center" valign="top" charoff="50">973 (89)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">264 (91)</td><td align="center" valign="top" charoff="50">709 (89)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Advanced stage</td><td align="center" valign="top" charoff="50">1448 (20)</td><td align="center" valign="top" charoff="50">116 (11)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">25 (9)</td><td align="center" valign="top" charoff="50">91 (11)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Screen-detected</td><td align="center" valign="top" charoff="50"><italic>N</italic>=1646</td><td align="center" valign="top" charoff="50"><italic>N</italic>=579</td><td align="char" valign="top" char="." charoff="50">0.441</td><td align="center" valign="top" charoff="50"><italic>N</italic>=163</td><td align="center" valign="top" charoff="50"><italic>N</italic>=416</td><td align="char" valign="top" char="." charoff="50">0.046</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Localised stage</td><td align="center" valign="top" charoff="50">1508 (92)</td><td align="center" valign="top" charoff="50">538 (93)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">157 (96)</td><td align="center" valign="top" charoff="50">381 (92)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Advanced stage</td><td align="center" valign="top" charoff="50">138 (8)</td><td align="center" valign="top" charoff="50">41 (7)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">6 (4)</td><td align="center" valign="top" charoff="50">35 (8)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Clinically diagnosed</td><td align="center" valign="top" charoff="50"><italic>N</italic>=5772</td><td align="center" valign="top" charoff="50"><italic>N</italic>=510</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td><td align="center" valign="top" charoff="50"><italic>N</italic>=126</td><td align="center" valign="top" charoff="50"><italic>N</italic>=384</td><td align="char" valign="top" char="." charoff="50">0.891</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Localised stage</td><td align="center" valign="top" charoff="50">4462 (77)</td><td align="center" valign="top" charoff="50">435 (85)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">107 (85)</td><td align="center" valign="top" charoff="50">328 (85)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Advanced stage</td><td align="center" valign="top" charoff="50">1310 (23)</td><td align="center" valign="top" charoff="50">75 (15)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">19 (15)</td><td align="center" valign="top" charoff="50">56 (15)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50">
<bold>PSA at screening</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Screening arm</td><td align="center" valign="top" charoff="50"><italic>N</italic>=23&#x02009;770</td><td align="center" valign="top" charoff="50"><italic>N</italic>=4605</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td><td align="center" valign="top" charoff="50"><italic>N</italic>=2142</td><td align="center" valign="top" charoff="50"><italic>N</italic>=2463</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;PSA &#x0003c;4 ng&#x02009;ml<sup>&#x02212;1</sup></td><td align="center" valign="top" charoff="50">19&#x02009;908 (84)</td><td align="center" valign="top" charoff="50">4016 (87)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">1989 (93)</td><td align="center" valign="top" charoff="50">2027 (82)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;PSA &#x02a7e;4&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup></td><td align="center" valign="top" charoff="50">3862 (16)</td><td align="center" valign="top" charoff="50">589 (13)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">153 (7)</td><td align="center" valign="top" charoff="50">436 (18)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviations: PRS=polygenic risk score; PSA=prostate specific antigen.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4"><label>Table 4</label><caption><title>Summary of the estimates used to derive the proportion of overdiagnosis by polygenic risk
groups</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">
<bold>Overall</bold>
</th><th align="center" valign="top" charoff="50">
<bold>Lower risk group</bold>
</th><th align="center" valign="top" charoff="50">
<bold>Higher risk group</bold>
</th><th align="center" valign="top" charoff="50">
<bold>95&#x00025; CI</bold>
</th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50">
<bold>Estimates used to derive expected number of screen-detected cancers</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Sensitivity (<italic>S</italic>)<xref ref-type="fn" rid="t4-fn1">a</xref></td><td align="center" valign="top" charoff="50">0.55</td><td align="center" valign="top" charoff="50">0.55</td><td align="center" valign="top" charoff="50">0.55</td><td align="center" valign="top" charoff="50">0.45&#x02013;0.65</td></tr><tr><td align="left" valign="top" charoff="50">Inverse of mean sojourn time (<italic>&#x003bb;</italic>)<xref ref-type="fn" rid="t4-fn1">a</xref></td><td align="center" valign="top" charoff="50">0.16</td><td align="center" valign="top" charoff="50">0.16</td><td align="center" valign="top" charoff="50">0.16</td><td align="center" valign="top" charoff="50">0.12&#x02013;0.24</td></tr><tr><td align="left" valign="top" charoff="50">Baseline incidence rate (cases/person-years) (<italic>I</italic>&#x0002a;)</td><td align="center" valign="top" charoff="50">0.00617</td><td align="center" valign="top" charoff="50">0.00247<xref ref-type="fn" rid="t4-fn2">b</xref></td><td align="center" valign="top" charoff="50">0.00990<xref ref-type="fn" rid="t4-fn3">c</xref></td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">
<bold>Sampling fractions</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">No cancer (<italic>&#x003b1;</italic><sub><italic>p</italic></sub>)</td><td align="center" valign="top" charoff="50">1.000</td><td align="center" valign="top" charoff="50">0.502</td><td align="center" valign="top" charoff="50">0.498</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Prevalent screen-detected cancer</td><td align="center" valign="top" charoff="50">1.000</td><td align="center" valign="top" charoff="50">0.243</td><td align="center" valign="top" charoff="50">0.757</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Incident screen-detected cancer</td><td align="center" valign="top" charoff="50">1.000</td><td align="center" valign="top" charoff="50">0.298</td><td align="center" valign="top" charoff="50">0.702</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Interval cancer</td><td align="center" valign="top" charoff="50">1.000</td><td align="center" valign="top" charoff="50">0.200</td><td align="center" valign="top" charoff="50">0.800</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><label>a</label><p><italic>S</italic> and <italic>&#x003bb;</italic> were derived from data on men in the lower and higher risk
groups combined.</p></fn><fn id="t4-fn2"><label>b</label><p><italic>R</italic><sub>l</sub>.</p></fn><fn id="t4-fn3"><label>c</label><p><italic>R</italic><sub>h</sub>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl5"><label>Table 5</label><caption><title>Proportion of screen-detected cancers which are likely to be overdiagnosed by polygenic
risk</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">
<bold>Screening round</bold>
</th><th align="center" valign="top" charoff="50">
<bold>No. of screening episodes</bold>
</th><th align="center" valign="top" charoff="50">
<bold>No. of screen-detected cancer</bold>
</th><th align="center" valign="top" charoff="50">
<bold>Expected no. of non-overdiagnosed screen-detected cancer</bold>
</th><th align="center" valign="top" charoff="50">
<bold>Per cent</bold>
<bold>(&#x00025;) overdiagnosis (95&#x00025; CI)</bold>
</th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50">
<bold>Overall</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">Screening round 1</td><td align="center" valign="top" charoff="50">23&#x02009;771</td><td align="center" valign="top" charoff="50">686</td><td align="center" valign="top" charoff="50">504</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Screening round 2</td><td align="center" valign="top" charoff="50">18&#x02009;044</td><td align="center" valign="top" charoff="50">596</td><td align="center" valign="top" charoff="50">272</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Screening round 3</td><td align="center" valign="top" charoff="50">10&#x02009;328</td><td align="center" valign="top" charoff="50">364</td><td align="center" valign="top" charoff="50">173</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Total</td><td align="center" valign="top" charoff="50">52&#x02009;143</td><td align="center" valign="top" charoff="50">1646</td><td align="center" valign="top" charoff="50">949</td><td align="center" valign="top" charoff="50">42 (37&#x02013;52)</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">
<bold>PRS risk groups</bold>
<hr/></td></tr><tr><td align="left" valign="top" charoff="50">
<bold>Lower risk group</bold>
</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Screening round 1</td><td align="center" valign="top" charoff="50">11&#x02009;938</td><td align="center" valign="top" charoff="50">167</td><td align="center" valign="top" charoff="50">101</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Screening round 2</td><td align="center" valign="top" charoff="50">9062</td><td align="center" valign="top" charoff="50">178</td><td align="center" valign="top" charoff="50">55</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Screening round 3</td><td align="center" valign="top" charoff="50">5187</td><td align="center" valign="top" charoff="50">108</td><td align="center" valign="top" charoff="50">35</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Total</td><td align="center" valign="top" charoff="50">26&#x02009;186</td><td align="center" valign="top" charoff="50">453</td><td align="center" valign="top" charoff="50">191</td><td align="center" valign="top" charoff="50">58 (54&#x02013;65)</td></tr><tr><td align="left" valign="top" charoff="50">
<bold>Higher risk group</bold>
</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Screening round 1</td><td align="center" valign="top" charoff="50">11&#x02009;833</td><td align="center" valign="top" charoff="50">519</td><td align="center" valign="top" charoff="50">402</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Screening round 2</td><td align="center" valign="top" charoff="50">8982</td><td align="center" valign="top" charoff="50">418</td><td align="center" valign="top" charoff="50">217</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Screening round 3</td><td align="center" valign="top" charoff="50">5141</td><td align="center" valign="top" charoff="50">256</td><td align="center" valign="top" charoff="50">139</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Total</td><td align="center" valign="top" charoff="50">25&#x02009;957</td><td align="center" valign="top" charoff="50">1193</td><td align="center" valign="top" charoff="50">758</td><td align="center" valign="top" charoff="50">37 (31&#x02013;47)</td></tr></tbody></table></table-wrap></floats-group></article>